A 51-year-old man was diagnosed with muscle-invasive urothelial bladder carcinoma
with a transurethral resection of the bladder (TURB) in February 2016. The radiological
staging with whole-body computed tomography (CT) scan and 18-fluorine fluorodeoxyglucose
positron emission tomography (PET/CT) scan revealed multiple bone and lymph node metastases
(enlarged mediastinal, retroperitoneal and pelvic lymph nodes).
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to European Journal of CancerAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing.Nat Biotechnol. 2013; 31: 1023-1031
- Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib.Cancer Discov. 2014; 4: 546-553
- Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer.J Clin Oncol. 2013; 31: 3133-3140
- Comprehensive molecular characterization of muscle-invasive bladder cancer.Cell. 2017; 171 (540–556.e25)
- Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase.Nature. 2005; 434: 913-917
- Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy.Nature. 2005; 434: 917-921
- The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.Mol Oncol. 2011; 5: 387-393
- BRCAness revisited.Nat Rev Cancer. 2016; 16: 110-112
- DNA-repair defects in metastatic prostate cancer.N Engl J Med. 2015; 373: 1697-1708
- DNA damage repair and response (DDR) gene alterations (alt) and response to PD1/PDL1 blockade in platinum-treated metastatic urothelial carcinoma (mUC).J Clin Oncol. May 2017; 35 (4509–4509)https://doi.org/10.1200/JCO.2017.35.15_suppl.4509
- A phase II study of cabozantinib in patients (pts) with relapsed or refractory metastatic urothelial carcinoma (mUC).J Clin Oncol. 2016; 34 (suppl; abstr 4534)
- Molecular drivers of the non-T-cell-inflamed tumor microenvironment in urothelial bladder cancer.Cancer Immunol Res. 2016; 4: 563-568
Article info
Publication history
Published online: April 18, 2018
Accepted:
March 19,
2018
Received in revised form:
March 13,
2018
Received:
December 24,
2017
Identification
Copyright
© 2018 Elsevier Ltd. All rights reserved.
